Sotera Health Company — Form 8-K Summary
Reporting date: March 9, 2021. The filing reports that Sotera Health issued its fourth-quarter and full-year 2020 financial results and related investor presentation.
Business Context and Reporting Period
The filing concerns results for the quarter and year ended December 31, 2020. Sotera Health is incorporated in Delaware and trades on Nasdaq under the symbol SHC.
Financial Results and Key Metrics
The filing itself does not provide clear values for revenue, net income, cash flow, margins, debt, liquidity, or other financial metrics. Those details were included in the referenced press release and investor presentation, which were furnished as Exhibits 99.1 and 99.2 but are not included in the supplied filing text.
The company stated that the press release and investor presentation include non-GAAP financial information and reconciliations to comparable GAAP measures.
Changes Versus Prior Period
The supplied filing text does not provide specific year-over-year or quarter-over-quarter changes. These comparisons may be contained in the referenced exhibits.
Guidance, Outlook, Risks, and Unusual Items
Management scheduled a conference call to discuss the 2020 fourth-quarter and full-year results and the company’s full-year 2021 outlook. Specific guidance figures, commentary, risks, contingencies, and unusual items are not provided in the filing text.
The financial results and investor presentation were furnished under Items 2.02 and 7.01 and are not deemed filed for purposes of Section 18 of the Exchange Act or incorporated by reference unless expressly stated.
Investor Verification Checklist
- Verify 2020 fourth-quarter and full-year revenue, profit, adjusted earnings, and operating cash flow in Exhibit 99.1.
- Review the reconciliation of non-GAAP measures to GAAP results.
- Confirm full-year 2021 revenue, earnings, cash flow, and other guidance metrics.
- Review debt balances, liquidity, covenant requirements, and capital allocation information.
- Assess management’s discussion of COVID-19 impacts, operational risks, contingencies, and unusual items in the exhibits.